VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Bristol-Myers Squibb Company vs Cboe Global Markets, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisCboe Global Markets, Inc.
CBOE · Cboe BZX
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Cboe Global Markets, Inc.'s moat claims, evidence, and risks.
View CBOE analysisComparison highlights
- Moat score gap: Cboe Global Markets, Inc. leads (76 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)); Cboe Global Markets, Inc. has 5 segments (60.8% in Options).
- Moat breadth: Bristol-Myers Squibb Company has 4 moat types across 3 domains; Cboe Global Markets, Inc. has 8 across 4.
Primary market context
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Cboe Global Markets, Inc.
Options
U.S. listed options exchanges (multi-listed + proprietary index options)
United States
Broker-dealers, market makers, institutional investors, retail order-flow intermediaries
Exchange operator (SRO) + derivatives listing venue + market data provider
60.8%
Side-by-side metrics
Moat coverage
Shared moat types
Bristol-Myers Squibb Company strengths
Cboe Global Markets, Inc. strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Cboe Global Markets, Inc. segments
Full profile >Options
Oligopoly
North American Equities
Competitive
Europe and Asia Pacific
Oligopoly
Futures
Quasi-Monopoly
Global FX
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.